[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571209":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":25,"studyPopulation":25,"armGroups":32,"interventions":42,"overallOfficials":52,"centralContacts":57,"locations":66,"responsibleParty":81,"collaborators":25,"id":83,"slug":25,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":25,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":25,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":25,"overallStatus":69,"whyStopped":25,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Nurix Therapeutics, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":25,"otherOutcomes":25},[9,13,15,18,21,23],{"measure":10,"description":11,"timeFrame":12},"Assessment of PK parameters: NX-5948 tablets versus capsules","Relative bioavailability of NX-5948 tablet, compared to capsule, will be measured using PK parameters (AUC)","9 weeks",{"measure":10,"description":14,"timeFrame":12},"Relative bioavailability of NX-5948 tablet, compared to capsule, will be measured using PK parameters (Cmax)",{"measure":16,"description":17,"timeFrame":12},"Assessment of PK parameters NX-5948 tablets versus capsules","Relative bioavailability of NX-5948 tablet, compared to capsule, will be measured using PK parameters (Tmax)",{"measure":19,"description":20,"timeFrame":12},"Food effect and effect of esomeprazole on AUC0-t for single-dose NX-5948 tablet","Evaluate the effect of food and the effect of multiple doses of esomeprazole on the single-dose PK of NX-5948 tablet",{"measure":22,"description":20,"timeFrame":12},"Food effect and effect of esomeprazole on AUC0-inf for single-dose NX-5948 tablet",{"measure":24,"description":20,"timeFrame":12},"Food effect and effect of esomeprazole on Cmax for single-dose NX-5948 tablet",null,{"allocation":27,"interventionModel":28,"interventionModelDescription":25,"primaryPurpose":29,"observationalModel":25,"timePerspective":25,"maskingInfo":30},"NON_RANDOMIZED","PARALLEL","TREATMENT",{"masking":31,"maskingDescription":25,"whoMasked":25},"NONE",[33,38],{"label":34,"type":35,"description":25,"interventionNames":36},"NX-5948 tablet and capsule under fasted and fed conditions","EXPERIMENTAL",[37],"Drug: NX-5948",{"label":39,"type":35,"description":25,"interventionNames":40},"NX-5948 tablet and capsule combined with esomeprazole under fasted conditions",[37,41],"Drug: Esomeprazole",[43,48],{"type":44,"name":45,"description":46,"armGroupLabels":47,"otherNames":25},"DRUG","NX-5948","Administered orally in tablet or capsule form",[39,34],{"type":44,"name":49,"description":50,"armGroupLabels":51,"otherNames":25},"Esomeprazole","Administered orally in capsule form",[39],[53],{"name":54,"affiliation":55,"role":56},"Study Director","Nurix Therapeutics","STUDY_DIRECTOR",[58,63],{"name":59,"role":60,"phone":61,"phoneExt":25,"email":62},"Angie Badgett, MBA","CONTACT","402-437-6351","angie.badgett@celerion.com",{"name":64,"role":60,"phone":61,"phoneExt":25,"email":65},"Allen Hunt, MD","allen.hunt@celerion.com",[67],{"facility":68,"status":69,"city":70,"state":71,"zip":72,"country":73,"countryCode":74,"cosmosGeoPoint":75,"geoPoint":80,"contacts":25},"Celerion","RECRUITING","Lincoln","Nebraska","68502","United States","US",{"type":76,"coordinates":77},"Point",[78,79],-96.66696,40.8,{"lat":79,"lon":78},{"type":82,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100571209",false,"NCT06717269","Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets","A Phase 1, Open-Label Study in Healthy Volunteers to Evaluate the Relative Bioavailability of NX-5948 Tablets Compared to Capsules, and the Effect of Food and an Acid-reducing Agent on the Pharmacokinetics of NX-5948","Key Inclusion Criteria:\n\n* Healthy, adult, male or female 19-55 years of age\n* Continuous non-smoker who has not used nicotine and tobacco-containing products for at least 3 months prior to the first dosing\n* Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg\u002Fm2\n* Medically healthy with no clinically significant medical history, physical examination, clinical laboratory profiles, vital signs, or 12-lead safety ECGs at the screening visit, as deemed by the PI or designee\n* Understands the study procedures in the informed consent form (ICF) and be willing and able to comply with the protocol.\n\nKey Exclusion Criteria:\n\n* Mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study\n* Clinically significant history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neoplastic myeloproliferative, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine or connective tissue diseases or disorders\n* History of any gastrointestinal surgery or cholecystectomy that could impact the PK of NX-5948\n* History or presence of alcohol or drug abuse within the past 2 years\n* History or presence of hypersensitivity, angioedema, or idiosyncratic reaction to the study drug(s) or related compounds\n* History or presence of:\n\n  * Significant multiple and\u002For severe allergies, including anaphylactic reaction.\n  * Personal or family history of prolonged QT syndrome or family history of sudden cardiac death.\n  * Evidence of atrial fibrillation, atrial flutter, complete bundle branch block, Wolff Parkinson-White Syndrome, or cardiac pacemaker.\n  * Adrenal insufficiency.\n  * Skin infection.\n* Female volunteers of childbearing potential\n* Female volunteer with a positive pregnancy test\n* Positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) at the screening visit\n* Donation of blood or significant blood loss within 56 days prior to the first dosing\n* Plasma donation within 7 days prior to the first dosing\n* History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.\n* Previous exposure to NX-5948.\n* Participation in another clinical study within 30 days or within 5 half-lives (if known), prior to the first dosing, whichever is longer. The 30-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.",true,"ALL","19 Years","55 Years",{"count":94,"type":95},18,"ESTIMATED","INTERVENTIONAL",[98],"PHASE1","This is a multiple part, multiple cohort study evaluating the relative bioavailability, food effect, and drug-drug interaction of NX-5948 in healthy volunteers.",[101],"Healthy Volunteer","2026-02-03",{"date":104,"type":105},"2026-02-05","ACTUAL",{"date":107,"type":105},"2024-11-30",{"date":109,"type":95},"2026-08",{"name":5,"class":6},1]